Quince Therapeutics, Inc. has announced a major leadership transition, appointing Dr. Brigette Roberts as its new Chief Executive Officer and John Militello as Chief Financial Officer. This restructuring comes as the company prepares to rebrand itself as IRulya Therapeutics, effective October 9, 2026. These changes reflect a strategic shift aimed at strengthening the company’s position in the biological products industry.
Dr. Roberts, who previously served as the Chief Corporate Affairs Officer and a board member since May 2026, brings a wealth of experience to her new role. She has a strong background in the biotech industry, having led Orphai Therapeutics as CEO prior to joining Quince. Her leadership at Orphai was marked by the development of a differentiated pulmonary franchise and securing significant funding for research and development.
Militello, appointed as CFO, has a robust background in finance within the biotech sector, having previously held senior financial roles at Rocket Pharmaceuticals and Immune Pharmaceuticals. His experience is expected to bolster Quince’s financial strategies as it navigates the competitive landscape of biological products.
Background
Quince Therapeutics, Inc., incorporated in California, operates in the biological products sector, specifically focusing on products that do not include diagnostic substances. The company trades on the Nasdaq under the ticker symbol QNCX. Its recent filings indicate a commitment to innovation and growth within this specialized industry.
What the Filing Says
According to the recent SEC filing (accession number 0001193125-26-418538), effective October 8, 2026, Dr. Roberts was appointed as CEO, succeeding Dirk Thye, who resigned from his positions. The filing also notes that John Militello has been appointed as CFO, succeeding Brendan Hannah. The company is set to undergo a name change to IRulya Therapeutics, effective immediately.
Impact
This leadership change may significantly affect Quince’s strategic direction and operational capabilities. The appointments of Roberts and Militello are expected to enhance the company's focus on developing innovative biological products, potentially positioning it more competitively against other firms in the sector.
What's Next
The filing does not specify what happens next beyond the leadership appointments and rebranding. However, stakeholders will likely be watching closely for further developments as the company implements its new strategic direction.